English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

An ELISA to detect a glycoprotein T AA-specific immune complexe (lC) has been developed utili zing a murine monoclonal antibody, AD1-40F4. that recognizes a 90kD subunit ofthe antigen. In this study we determined the applicability of the assay to assess the presence of the glycoprotein TAA-IC in lung cancer patients. The incidence of glycoprotein TAA-IC was 63% (33/89), significantly higher (p &lt;0.05) than normal controls (3.2%; 8/250). Comparative analyses of preand post-operative sera of non-small cell lung cancer patients revealed that in 30% (20/66) of patients. the ELISA va lue for the marker did not become negative, i.e., decrease below the cut-off level (0.410 OD nm ) after surgical resection of the tumor. It is postulated that these patients either had ex tensive disease or microscopic metastases that were not resectable. Evaluation of post-operative glycoprotein TAA-IC results in relation to disease recurrence revealed a significant association between the presence of the antigen in serum and disease recurrence. There did not appear to be any association between the glycoprotein TAA-IC and the other conventional marker, CEA; however, using more than one marker increases the incidence of detection of the disease.

Prognostic Value of a 90Kd Subunit Containing Glycoprotein Tumor-Associated Antigen Specific Immune Complexes in Lung Cancer Patients